2015 American Transplant Congress
Defining the Role of CD57+CD4 T Cells in Belatacept-Resistant Rejection
1Duke University, Durham, NC; 2Emory University, Atlanta, GA; 3Bristol-Myers Squibb, Princeton, NJ.
Purpose: We have shown that CD57+PD1- CD4 T cells are present in higher numbers in the peripheral blood and allograft biopsies of patients who experienced…2015 American Transplant Congress
ASKP1240 in De Novo Kidney Transplant Recipients
Primary objective was to evaluate the efficacy and safety of ASKP1240, antagonistic anti-CD40 antibody, in either a CNI free regimen or a CNI minimization regimen…2015 American Transplant Congress
Pharmacist-Led Renal-Sparing Conversion to Everolimus After Liver Transplantation
1Barnes-Jewish Hospital, St. Louis, MO; 2Washington University in St. Louis, St. Louis, MO.
Purpose: Preservation of renal function following orthotopic liver transplantation (OLT) through calcineurin inhibitor (CNI)-minimization is an established clinical objective. The use of everolimus (EVR) to…2015 American Transplant Congress
Immunomodulation of Human T Cells by a Novel RALG Preparation With Higher Specificity Toward Activating T Cells
Surgery, Duke University Medical Center, Durham, NC.
Current induction therapy using thymoglobulin (ATG) results in nonspecific T cell depletion. We have generated a polyclonal rabbit anti-human leukocyte globulin (RALG) by immunizing rabbits…2015 American Transplant Congress
Third Party Mesenchymal Stromal Cell Infusion in Kidney Transplant Recipient: 6-Month Safety Interim Analysis
Back-groundMesenchymal stromal cell (MSC) have immunomodulating properties and could be used as immunosuppressive agents.We report the 6-month safety results for the 5 first patients treated…2015 American Transplant Congress
Pharmacogenomic Predictors of Acute Rejection in Kidney Transplant Recipients Identified Using a DNA Biobank Linked to Electronic Medical Records
Purpose: Risk for acute rejection (AR) complicating transplant immunosuppression may be affected by frequent variants in pharmacogenes. Using a DNA biobank linked to electronic medical…2015 American Transplant Congress
Interference of Therapeutic Antibodies Used in Desensitization Protocols On Lymphocytotoxicity Crossmatch Results
Background: Therapeutic antibodies used to desensitize patients awaiting a human leukocyte antigen (HLA) or ABO-mismatched graft are suspected to interfere with the lymphocytotoxicity crossmatch (LCT-XM)…2015 American Transplant Congress
CMV prevalence in Mauritian and Indonesian Cynomolgus Macaques: Significance in Transplantation and CMV Disease Models
Despite the finding that most macaques express high serologic titers of anti-CMV antibody, susceptibility to disease appears to be variable post-transplant. This observation led us…2015 American Transplant Congress
Steroid-Free Quadruple Induction Regimen With Basiliximab, Everolimus, Mycophenolate and Very Low Dose Tacrolimus Reduces Incidence of Biopsy-Proven Acute Rejection and Toxicity Profile Compared to the Standard Triple Regimen
Department of Renal Transplantation Surgery, Sapporo Hokuyu Hospital, Sapporo, Japan.
Objectives: Nephrotoxicity of calcineurin inhibitors (CNI) in kidney allografts has been a significant clinical problem even with low exposure regimens. On the other hand, CNI-free…2015 American Transplant Congress
Safety and Efficacy of Low Dose and Very Low Dose Extended-Release Tacrolimus / MMF in De Novo Kidney Transplant Recipients
Recently, once-daily tacrolimus extended-release formulation (TACER) has been accepted in kidney transplantation, however its optimal dosing are not well evaluated. We have validated low dose…
- « Previous Page
- 1
- …
- 121
- 122
- 123
- 124
- 125
- …
- 138
- Next Page »